Call Options

27 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.94 - $1.55 $312,738 - $515,685
-332,700 Reduced 77.09%
98,900 $130,000
Q2 2024

Aug 15, 2024

SELL
$0.86 - $1.63 $226,696 - $429,668
-263,600 Reduced 37.92%
431,600 $440,000
Q1 2024

May 07, 2024

BUY
$1.27 - $2.24 $690,880 - $1.22 Million
544,000 Added 359.79%
695,200 $1.27 Million
Q4 2023

Feb 14, 2024

BUY
$0.8 - $1.28 $1,040 - $1,664
1,300 Added 0.87%
151,200 $187,000
Q3 2023

Nov 14, 2023

BUY
$0.87 - $1.84 $23,838 - $50,416
27,400 Added 22.37%
149,900 $170,000
Q2 2023

Aug 11, 2023

SELL
$0.51 - $1.43 $6,120 - $17,160
-12,000 Reduced 8.92%
122,500 $112,000
Q1 2023

May 16, 2023

BUY
$0.56 - $1.15 $40,656 - $83,490
72,600 Added 117.29%
134,500 $75,000
Q4 2022

Feb 14, 2023

SELL
$0.25 - $0.58 $5,125 - $11,890
-20,500 Reduced 24.88%
61,900 $35,000
Q3 2022

Nov 14, 2022

SELL
$0.3 - $0.46 $2,670 - $4,094
-8,900 Reduced 9.75%
82,400 $26,000
Q2 2022

Aug 15, 2022

SELL
$0.32 - $0.67 $73,024 - $152,894
-228,200 Reduced 71.42%
91,300 $32,000
Q1 2022

May 16, 2022

BUY
$0.72 - $2.93 $190,800 - $776,450
265,000 Added 486.24%
319,500 $230,000
Q4 2021

Feb 14, 2022

SELL
$2.26 - $3.34 $170,177 - $251,502
-75,300 Reduced 58.01%
54,500 $123,000
Q3 2021

Nov 15, 2021

SELL
$2.35 - $3.88 $241,815 - $399,252
-102,900 Reduced 44.22%
129,800 $374,000
Q2 2021

Aug 11, 2021

BUY
$2.83 - $4.2 $120,558 - $178,920
42,600 Added 22.41%
232,700 $882,000
Q1 2021

May 17, 2021

BUY
$2.92 - $5.06 $91,396 - $158,378
31,300 Added 19.71%
190,100 $643,000
Q4 2020

Feb 16, 2021

SELL
$2.22 - $3.78 $522,144 - $889,056
-235,200 Reduced 59.7%
158,800 $445,000
Q3 2020

Nov 16, 2020

SELL
$2.39 - $13.08 $312,612 - $1.71 Million
-130,800 Reduced 24.92%
394,000 $989,000
Q2 2020

Aug 14, 2020

BUY
$6.67 - $13.58 $2.25 Million - $4.58 Million
337,000 Added 179.45%
524,800 $7.13 Million
Q1 2020

May 15, 2020

BUY
$4.1 - $10.24 $514,959 - $1.29 Million
125,600 Added 201.93%
187,800 $1.42 Million
Q4 2019

Feb 14, 2020

SELL
$3.16 - $6.73 $56,248 - $119,794
-17,800 Reduced 22.25%
62,200 $393,000
Q3 2019

Nov 14, 2019

SELL
$3.55 - $5.4 $89,815 - $136,620
-25,300 Reduced 24.03%
80,000 $314,000
Q2 2019

Aug 14, 2019

SELL
$4.1 - $8.05 $469,449 - $921,725
-114,500 Reduced 52.09%
105,300 $510,000
Q1 2019

May 15, 2019

SELL
$5.41 - $8.73 $43,280 - $69,840
-8,000 Reduced 3.51%
219,800 $1.8 Million
Q4 2018

Feb 14, 2019

BUY
$5.39 - $9.15 $993,915 - $1.69 Million
184,400 Added 424.88%
227,800 $1.26 Million
Q3 2018

Nov 14, 2018

BUY
$7.44 - $10.65 $146,568 - $209,805
19,700 Added 83.12%
43,400 $383,000
Q2 2018

Aug 14, 2018

BUY
$9.15 - $11.34 $34,770 - $43,092
3,800 Added 19.1%
23,700 $237,000
Q3 2017

Nov 14, 2017

BUY
$13.06 - $19.67 $259,894 - $391,433
19,900
19,900 $391,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $329M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.